Safety and Effects of the ZenoBlazt+ and ZenoGenez+ Dietary Supplements on Antiaging in Middle-aged Adults and the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20241203001

Enrollment

Registered

2024-12-03

Start date

2025-01-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy conditions Middle-aged adults Elderly

Interventions

ZenoBlazt+ and ZenoGenez+ are a dietary supplement according to Thai Food and Drug Administration.,Placebo contains no active ingredient.

Experimental Dietary Supplement,Placebo Comparator Other

ZenoBlazt+ and ZenoGenez+,Placebo

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age between 50-70 years; 2. Body mass index within the range of 18.5-24.9 kg/m2; 3. General good health based on medical history, physical examination, and basic laboratory tests; and 4. Able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of any severe co-morbidity(ies), uncontrolled medical condition(s), or medical illness(es); 2. Presence of any significant inflammation, chronic disorders, infectious diseases, immune deficiencies, autoimmune disorders, and coagulopathy; 3. Anemia; 4. Insomnia or psychiatric disorders; 5. Headache disorders; 6. History of hypersensitivity to any ingredients in the investigational product; 7. History of alcoholism; 8. Heavy smoking or substance use; 9. Uses a drug(s), herb(s), antioxidant supplement(s), or dietary supplement(s) that may significantly affect study outcomes; 10. Uses antibiotic drugs, anti-inflammatory drugs, anti-thrombotic drugs, anti-platelet drugs, or immunosuppressant drugs or steroids; 11. Aesthetic intervention; 12. Physical attributes or skin conditions; and 13. Participates in another clinical trial.

Design outcomes

Primary

Measure	Time frame
Safety Day 0, Day 60, Day 120 History taking, physical examination and laboratory assessments	—

Secondary

Measure	Time frame
Skin parameters Day 0, Day 60, Day 120 Visiometer, Corneometer, Colorimeter, Cutometer, TEWA meter, and Mexameter,Quality of life and sleep quality Day 0, Day 60, Day 120 Questionnaire,Satisfaction Day 60, Day 120 Questionnaire,Exploratory outcomes Day 0, Day 60, Day 120 PhenoAge, telomere length, epigenetic aging clock/GrimAge, senescence-associated secretory phenotype and inflammation, antioxidant capacity	—

Measure

Time frame

Skin parameters Day 0, Day 60, Day 120 Visiometer, Corneometer, Colorimeter, Cutometer, TEWA meter, and Mexameter,Quality of life and sleep quality Day 0, Day 60, Day 120 Questionnaire,Satisfaction Day 60, Day 120 Questionnaire,Exploratory outcomes Day 0, Day 60, Day 120 PhenoAge, telomere length, epigenetic aging clock/GrimAge, senescence-associated secretory phenotype and inflammation, antioxidant capacity

—

Countries

Thailand

Contacts

Public ContactNut Koonrungsesomboon

Chiang Mai University

nkoonrung@gmail.com053935353

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026